AVTX-801
19-005271
Phase 2 small_molecule active
Quick answer
AVTX-801 for SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active